Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom

Delayed Oral LY333013 Rescues Mice from Highly Neurotoxic, Lethal Doses of Papuan Taipan (Oxyuranus scutellatus) Venom

There is an unmet need for economical snakebite therapies with long shelf lives that are effective even with delays in treatment. The orally bioavailable, heat-stable, secretory phospholipase A2 (sPLA2) inhibitor, LY333013, demonstrates antidotal characteristics for severe snakebite envenoming in bo...

Full description

Bibliographic Details
Main Authors:	Matthew R. Lewin, José María Gutiérrez, Stephen P. Samuel, María Herrera, Wendy Bryan-Quirós, Bruno Lomonte, Philip E. Bickler, Tommaso C. Bulfone, David J. Williams
Format:	Article
Language:	English
Published:	MDPI AG 2018-09-01
Series:	Toxins
Subjects:	snakebite envenoming neglected tropical disease field antidote inhibitor taipan PLA2 phospholipase A2 neurotoxicity antivenom
Online Access:	http://www.mdpi.com/2072-6651/10/10/380

Similar Items

Oral and IV Varespladib Rescue Experiments in Juvenile Pigs with Weakness Induced by Australian and Papuan <i>Oxyuranus scutellatus</i> Venoms
by: Lyndi L. Gilliam, et al.
Published: (2023-09-01)

Intra-Specific Venom Variation in the Australian Coastal Taipan <i>Oxyuranus scutellatus</i>
by: Theo Tasoulis, et al.
Published: (2020-07-01)

Phospholipase A2 (PLA<sub>2</sub>) as an Early Indicator of Envenomation in Australian Elapid Snakebites (ASP-27)
by: Geoffrey K. Isbister, et al.
Published: (2020-10-01)

In-Vitro Neutralization of the Neurotoxicity of Coastal Taipan Venom by Australian Polyvalent Antivenom: The Window of Opportunity
by: Umesha Madhushani, et al.
Published: (2020-10-01)

Coagulopathy following bites by the Papuan taipan (Oxyuranus scutellatus canni).
by: Lalloo, D, et al.
Published: (1995)

The efficacy of antivenom in the treatment of bites by the Papuan taipan (Oxyuranus scutellatus canni).
by: Trevett, A, et al.
Published: (1995)

Severe envenomation by the taipan (Oxyuranus scutellatus)
by: Lalloo, D, et al.
Published: (1997)

Antivenom availability, delays and use in Australia
by: Geoffrey K. Isbister
Published: (2023-03-01)

A Bibliometric Study on Global Snakebite Research Indexed in Web of Science
by: Chuanzhu Lv, et al.
Published: (2023-10-01)

Electrophysiological findings in patients envenomed following the bite of a Papuan taipan (Oxyuranus scutellatus canni).
by: Trevett, A, et al.
Published: (1995)

Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation
by: Matthew Lewin, et al.
Published: (2016-08-01)

Classifying snakebite in South Africa: Validating a scoring system
by: Darryl Wood, et al.
Published: (2017-02-01)

Omics Meets Biology: Application to the Design and Preclinical Assessment of Antivenoms
by: Juan J. Calvete, et al.
Published: (2014-12-01)

Snake bites by the Papuan taipan (Oxyuranus scutellatus canni): paralysis, hemostatic and electrocardiographic abnormalities, and effects of antivenom.
by: Lalloo, D, et al.
Published: (1995)

Failure of 3,4-diaminopyridine and edrophonium to produce significant clinical benefit in neurotoxicity following the bite of Papuan taipan (Oxyuranus scutellatus canni).
by: Trevett, A, et al.
Published: (1995)

Current Knowledge on Snake Dry Bites
by: Manuela B. Pucca, et al.
Published: (2020-10-01)

Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms
by: José María Gutiérrez, et al.
Published: (2020-02-01)

Scaling up antivenom for snakebite envenoming in the Brazilian Amazon: a cost-effectiveness analysisResearch in context
by: Armand Zimmerman, et al.
Published: (2024-01-01)

Availability, accessibility and use of antivenom for snakebite envenomation in Africa with proposed strategies to overcome the limitations
by: Mahmood Muazu Dalhat, et al.
Published: (2023-06-01)

Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms
by: Andreas Hougaard Laustsen, et al.
Published: (2018-07-01)

Priority Actions and Progress to Substantially and Sustainably Reduce the Mortality, Morbidity and Socioeconomic Burden of Tropical Snakebite
by: Robert A. Harrison, et al.
Published: (2016-11-01)

Clinical Risk Factors Associated with Poor Outcomes in Snake Envenoming: A Narrative Review
by: Darryl Wood
Published: (2023-11-01)

Snake Venom Proteomics, Immunoreactivity and Toxicity Neutralization Studies for the Asiatic Mountain Pit Vipers, <i>Ovophis convictus</i>, <i>Ovophis tonkinensis</i>, and Hime Habu, <i>Ovophis okinavensis</i>
by: Choo Hock Tan, et al.
Published: (2021-07-01)

Daboia (Vipera) palaestinae Envenomation in 123 Horses: Treatment and Efficacy of Antivenom Administration
by: Sharon Tirosh-Levy, et al.
Published: (2019-03-01)

Circumstances and Consequences of Snakebite Envenomings: A Qualitative Study in South-Eastern Costa Rica
by: Jazmín Arias-Rodríguez, et al.
Published: (2020-01-01)

Development of a membrane-disruption assay using phospholipid vesicles as a proxy for the detection of cellular membrane degradation
by: Mátyás A. Bittenbinder, et al.
Published: (2024-06-01)

Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims
by: R. Manjunatha Kini, et al.
Published: (2018-12-01)

Towards better antivenoms: navigating the road to new types of snakebite envenoming therapies
by: Suthimon Thumtecho, et al.
Published: (2023-12-01)

Snake Antivenoms—Toward Better Understanding of the Administration Route
by: Erika Gamulin, et al.
Published: (2023-06-01)

Clinical predictors of early surgical intervention in patients with venomous snakebites
by: Hsiao-Yu Lu, et al.
Published: (2023-03-01)

Snakebite envenoming at MSF: A decade of clinical challenges and antivenom access issues
by: Julien Potet, et al.
Published: (2023-03-01)

<i>Bothrops lanceolatus</i> Envenoming in Martinique: A Historical Perspective of the Clinical Effectiveness of Bothrofav Antivenom Treatment
by: Dabor Resiere, et al.
Published: (2024-03-01)

Secreted Phospholipases A2 of Snake Venoms: Effects on the Peripheral Neuromuscular System with Comments on the Role of Phospholipases A2 in Disorders of the CNS and Their Uses in Industry
by: John B. Harris, et al.
Published: (2013-12-01)

Equatorial Spitting Cobra (<i>Naja sumatrana</i>) from Malaysia (Negeri Sembilan and Penang), Southern Thailand, and Sumatra: Comparative Venom Proteomics, Immunoreactivity and Cross-Neutralization by Antivenom
by: Choo Hock Tan, et al.
Published: (2022-07-01)

When to think about a Lachesis muta envenomation in the Western Brazilian Amazon: Lessons from a case report
by: Jacqueline de Almeida Gonçalves Sachett, et al.
Published: (2022-09-01)

Snakebite in the Hills and Mountains of Nepal
by: Sunil Bogati, et al.
Published: (2022-11-01)

Perspectives on snakebite envenoming care needs across different sociocultural contexts and health systems: A comparative qualitative analysis among US and Brazilian health providers
by: Eleanor Strand, et al.
Published: (2023-03-01)

Is coagulopathy a common consequence of a Vipera berus bite? A retrospective single centre study
by: Katarzyna Elżbieta Dyląg-Trojanowska, et al.
Published: (2018-12-01)

Innovative Immunization Strategies for Antivenom Development
by: Erick Bermúdez-Méndez, et al.
Published: (2018-11-01)

Proteomic Analysis, Immuno-Specificity and Neutralization Efficacy of Pakistani Viper Antivenom (PVAV), a Bivalent Anti-Viperid Antivenom Produced in Pakistan
by: Andy Shing Seng Lim, et al.
Published: (2023-04-01)